Effects of brain-derived neurotrophic factor (BDNF) on the cochlear nucleus in cats deafened as neonates

Kandathil, Cherian K.; Stakhovskaya, Olga; Leake, Patricia A.

doi:10.1016/j.heares.2016.10.011

Cited by 6 publications

(3 citation statements)

References 72 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, it is a challenge to evaluate the local distribution and action of BDNF in targeted brain regions. As shown in Table 1 , some precise local delivery methods have been proposed, including intra-hippocampal [ 407 ], intra-cortical [ 408 – 411 ], intra-nucleus accumbens [ 412 ], intranasal [ 413 , 414 ], and intra-cochlear [ 415 ] infusions. Preclinical studies have shown that the brain-specific delivery of BDNF is beneficial for promoting the expression of BDNF receptors, inducing lasting potentiation of synaptic transmission, and increasing neurogenesis and ectopic granule cells [ 416 , 417 ].…”

Section: Bdnf-targeting Strategies For Ad Modificationmentioning

confidence: 99%

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Gao

Zhang

Sterling

et al. 2022

Transl Neurodegener

186

View full text Add to dashboard Cite

Synaptic abnormalities are a cardinal feature of Alzheimer’s disease (AD) that are known to arise as the disease progresses. A growing body of evidence suggests that pathological alterations to neuronal circuits and synapses may provide a mechanistic link between amyloid β (Aβ) and tau pathology and thus may serve as an obligatory relay of the cognitive impairment in AD. Brain-derived neurotrophic factors (BDNFs) play an important role in maintaining synaptic plasticity in learning and memory. Considering AD as a synaptic disorder, BDNF has attracted increasing attention as a potential diagnostic biomarker and a therapeutical molecule for AD. Although depletion of BDNF has been linked with Aβ accumulation, tau phosphorylation, neuroinflammation and neuronal apoptosis, the exact mechanisms underlying the effect of impaired BDNF signaling on AD are still unknown. Here, we present an overview of how BDNF genomic structure is connected to factors that regulate BDNF signaling. We then discuss the role of BDNF in AD and the potential of BDNF-targeting therapeutics for AD.

show abstract

Section: Bdnf-targeting Strategies For Ad Modificationmentioning

confidence: 99%

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Gao

Zhang

Sterling

et al. 2022

Transl Neurodegener

186

View full text Add to dashboard Cite

show abstract

“…Cats have also been used extensively to study cochlear implantation due to the advantage of being anatomically similar to humans (Benovitski et al, 2014;George et al, 2014;Kandathil et al, 2016;Land et al, 2016;Ryugo et al, Note. Using genetic sequence information found on Ensembl.org, percentage of the orthologous sequence matching the human sequence of GJB2 is listed for each species.…”

Section: Using Animals To Model Hearing Lossmentioning

confidence: 99%

Emerging Therapies and Approaches to Treat and Prevent Hearing Loss

et al. 2020

View full text Add to dashboard Cite

Purpose More than 460 million people are impacted by disabling hearing loss worldwide. Hearing loss has negative impacts across the life span and varies by individual. Specifically, in children, hearing loss has been shown to affect learning outcomes, behavioral and cognitive growth, and psychosocial development. In adults, hearing loss has been shown to affect quality of life, social isolation, depression, and anxiety. The purpose of this review is to advance the understanding of the latest research in the development of new treatments of hearing loss, including gene therapy, stem cell therapy, and pharmacotherapies. We address the use of animals to model human hearing loss and the importance of animals in previous discoveries and developing new therapies. We highlight the importance of early identification for better speech and developmental outcomes specifically in pediatric individuals. Lastly, we review new possibilities in the prevention of hearing loss and the path to translation into practice. Conclusions Research and development of new therapies to treat hearing loss is an ever growing field with many notable successes. However, clinical translation still poses many challenges. Many discoveries related to gene therapy, stem cell therapy, and pharmacotherapy are in the early phases of clinical trials and hold promise. This review empowers audiologists to be aware of these most recent developments and be conscious of the evolving future landscape of treatment and management of hearing loss.

show abstract

“…R. Lim and A. Brichta [15] described the development of the human hearing organ with intussusception of the ear sac at 4 weeks of gestation, the growth of the semicircular canals from 5 weeks and the formation of the auricle from 10 weeks of gestation. A number of authors proved that from the 12th week, the vestibular node of the vestibulocochlear nerve was gradually filled with glial cells, and in the cochlear nerve, at the 22nd week, the peripheral processes began to be myelinated, which suggests that the maturation of peripheral glial cells in the hearing organ of the human fetus begins its development from 9 to 22 weeks of gestation [10,16,19].…”

Section: Introductionmentioning

confidence: 99%

Morphological features of the pons in human fetuses 14-15 weeks of intrauterine development

Lopatkina,

Tykholaz,

Shkolnikov

et al. 2024

Rep. of Morph.

View full text Add to dashboard Cite

Knowledge of human embryonic development is essential to improve our understanding of human fetal anatomy and for better understanding the etiology of congenital malformations. Currently, the structures of the posterior cranial fossa and the brain stem are of great interest to researchers, because of a large number of nuclei are located in the pons area, which play an important role in ensuring vital functions. The aim of the scientific work is to establish the morphological features of the pons of human fetuses at 14-15 weeks of gestation, the size and area of the nuclei of cranial nerves and neurons which are located in the area of the pons. Anatomical and histological research was carried out on 6 human fetuses aged 14-15 weeks of gestation. The cadaver material for research was obtained as a result of late abortions which were conducted according to medical indications in Vinnytsia maternity hospitals. Preparations were fixed in a 10 % solution of neutral formalin, stained with hematoxylin-eosin, toluidine blue modified by Nissl. Computer histometry (Toup View) was used for morphometric research. Statistical digital data were processed on a personal computer using Microsoft Excel 2016 and “Statistica 6.1” software. We established that in human fetuses at 14-15 weeks of intrauterine development, the nuclei of the trigeminal, abductor and vestibulocochlear nerves were detected. The nucleus of the facial nerve on 14-15 weeks of gestation is represented by single polygonal nerve cells with eosinophilic cytoplasm. The nucleus of the abductor nerve had the largest area, the cochlear nucleus of the vestibulocochlear nerve had the smallest area. The largest area of neurons was in the nuclei of the VIII pair of cranial nerve, the smallest – in the nucleus of the abductor and facial nerves. At 14-15 weeks of intrauterine development of human fetuses, the area of the cell nucleus could be determined only in the nuclei of the vestibulocochlear nerve, while the cell nuclei of the trigeminal, facial, and abductor nerves were represented by nerve cells of a spherical shape with a nucleus in which a basophilic nucleolus and a homogeneous eosinophilic cytoplasm were noted. Thus, in human fetuses of 14-15 weeks of intrauterine development, differences in the sizes and areas of the nuclei of cranial nerves and neurons that form nuclei in the pons area were found.

show abstract

Effects of brain-derived neurotrophic factor (BDNF) on the cochlear nucleus in cats deafened as neonates

Cited by 6 publications

References 72 publications

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential

Emerging Therapies and Approaches to Treat and Prevent Hearing Loss

Morphological features of the pons in human fetuses 14-15 weeks of intrauterine development

Contact Info

Product

Resources

About